Massimo Mineo

Massimo Mineo is Global Finance Director Business Unit Rare diseases at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.

He holds a Master’s degree in Business Administration and has spent over 20 years working in the pharmaceutical industry, particularly in the areas of Commercial and Finance.

He joined Sigma-Tau in 1998 where he served in various roles of growing responsibility in Finance and Administration in the holding company of the group. In 2008, he moved to become Head of Business Operations for the Italian market. At that time, he was also CEO of Lynapharm SA, a French joint venture company focused on hospital CNS products.

Prior to joining Recordati Rare Diseases in 2015, he was instrumental in establishing the new Sigma Tau Rare Diseases entity in order to acquire Enzon Pharmaceuticals’ rare diseases portfolio. He was also Head of Global International Business overseeing local offices in Spain, France, Benelux, Germany, UK, Switzerland, India, China and the US, as well as an extensive worldwide network of licensees/distributors.

Mid 2020 he is being instrumental in leading a global role at Basel for supporting business development and geographic expansion of Rare Diseases serving multiple stakeholders